Epidemiology of primary myelofibrosis (PMF), essential thrombocythemia (ET), and polycythemia vera (PV) in the European Union (EU)

被引：0
|
作者：
Mehta, J. [1 ]
Le-Ruyet, O. [2 ]
Fryzek, J. [3 ]
Iqbal, S. U. [1 ]
Mesa, R. [4 ]
机构：
[1] Sanofi Aventis, Evidence & Value Dev, Cambridge, MA USA
[2] Sanofi Aventis, Evidence & Value Dev, Chilly Mazarin, France
[3] Epidstat Inst, Ann Arbor, MI USA
[4] Mayo Clin, Div Hematol & Med Oncol, Scottsdale, AZ USA
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1489
引用
收藏
页码：S323 / S324
页数：2
相关论文
共 50 条
  • [41] Basophilia Predicts Poorer Outcomes in Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis, and Myeloproliferative Neoplasm, Unclassifiable
    Yuen, Lisa
    Gogakos, Tasos
    Boiocchi, Leonardo
    Hobbs, Gabriela
    Hasserjian, Robert
    AMERICAN JOURNAL OF HEMATOLOGY, 2024,
  • [42] Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey
    Ishida, Hisashi
    Miyajima, Yuji
    Hyakuna, Nobuyuki
    Hamada, Satoru
    Sarashina, Takeo
    Matsumura, Risa
    Umeda, Katsutsugu
    Mitsui, Tetsuo
    Fujita, Naoto
    Tomizawa, Daisuke
    Urayama, Kevin Y.
    Ishida, Yasushi
    Taga, Takashi
    Takagi, Masatoshi
    Adachi, Souichi
    Manabe, Atsushi
    Imamura, Toshihiko
    Koh, Katsuyoshi
    Shimada, Akira
    EJHAEM, 2020, 1 (01): : 86 - 93
  • [43] Clinical Features of Children with Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis in Japan: Retrospective Nationwide Survey
    Ishida, Hisashi
    Sarashina, Takeo
    Matsumura, Risa
    Umeda, Katsutsugu
    Mitsui, Tetsuo
    Fujita, Naoto
    Tomizawa, Daisuke
    Urayama, Kevin Y.
    Ishida, Yasushi
    Taga, Takashi
    Takagi, Masatoshi
    Adachi, Souichi
    Manabe, Atsushi
    Imamura, Toshihiko
    Koh, Katsuyoshi
    Shimada, Akira
    BLOOD, 2019, 134
  • [44] Phase II Study of Sunitinib in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
    Apostolidou, Effrosyni
    Kantarjian, Hagop
    Thomas, Deborah
    Burger, Ian
    Borthakur, Gautam
    Verstovsek, Srdan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (04): : 281 - 284
  • [45] Myelofibrotic Transformations of Polycythemia Vera and Essential Thrombocythemia are Morphologically, Biologically, and Prognostically Indistinguishable From Primary Myelofibrosis
    Sangle, Nikhil
    Cook, Josh
    Perkins, Sherrie
    Teman, Carolin J.
    Bahler, David
    Hickman, Kimberly
    Wilson, Andrew
    Prchal, Josef
    Salama, Mohamed E.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2014, 22 (09) : 663 - 668
  • [46] Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
    Barbui, T.
    Thiele, J.
    Vannucchi, A. M.
    Tefferi, A.
    BLOOD CANCER JOURNAL, 2015, 5 : e337 - e337
  • [47] Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement
    Sliwa, Thamer
    Beham-Schmid, Christine
    Burgstaller, Sonja
    Buxhofer-Ausch, Veronika
    Gastl, Guenther
    Geissler, Klaus
    Krauth, Maria
    Krippl, Peter
    Lang, Alois
    Petzer, Andreas
    Woehrer, Stefan
    Woelfler, Albert
    Gisslinger, Heinz
    WIENER KLINISCHE WOCHENSCHRIFT, 2017, 129 (9-10) : 293 - 302
  • [48] Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapy
    Tefferi, Ayalew
    AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (06) : 491 - 497
  • [49] The glucocorticoid receptor A3669G SNP is not associated with polycythemia vera, essential thrombocythemia or primary myelofibrosis
    Costache, Roxana M.
    Banescu, Claudia
    Popp, Radu A.
    Pop, Ioan V.
    Trifa, Adrian P.
    LEUKEMIA & LYMPHOMA, 2016, 57 (01) : 209 - 211
  • [50] Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement
    Thamer Sliwa
    Christine Beham-Schmid
    Sonja Burgstaller
    Veronika Buxhofer-Ausch
    Günther Gastl
    Klaus Geissler
    Maria Krauth
    Peter Krippl
    Alois Lang
    Andreas Petzer
    Stefan Wöhrer
    Albert Wölfler
    Heinz Gisslinger
    Wiener klinische Wochenschrift, 2017, 129 : 293 - 302
12345